{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vo HH"],"funding":["Support was provided in part by the National Institutes of Health/National Cancer Institute","Supported in part by donor funds from Mr. and Mrs. Steven McKenzie, Mr. and Mrs. Zane W. Arrott, and Jamie’s Hope for Dr. Tsimberidou’s Personalized Medicine Program","Supported in part by donor funds from Mr. and Mrs. Steven McKenzie, Mr. and Mrs. Zane W. Arrott, and Jamie's Hope for Dr. Tsimberidou's Personalized Medicine Program","The study was primarily supported by Sumitomo Dainippon Pharma Oncology, Cambridge, Massachusetts, USA"],"pagination":["1330"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8909492"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(5)"],"pubmed_abstract":["<b>Background</b>: BBI608 is an investigational reactive oxygen species generator that affects several molecular pathways. We investigated BBI608 combined with immune checkpoint inhibitors in patients with advanced cancers. <b>Methods</b>: BBI608 (orally twice daily) was combined with ipilimumab (3 mg/kg IV every 3 weeks); pembrolizumab (2 mg/kg IV every 3 weeks); or nivolumab (3 mg/kg IV every 4 weeks). We assessed the safety, antitumor activity and the pharmacokinetic profile of BBI combined with immunotherapy. <b>Results:</b> From 1/2017 to 3/2017, 12 patients were treated (median age, 54 years; range, 31-78; 6 men). Treatment was overall well tolerated. No dose-limiting toxicity was observed. The most common adverse events were diarrhea (5 patients: grade (G)1-2, <i>n</i> = 3; G3, <i>n"],"journal":["Cancers"],"pubmed_title":["Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center."],"pmcid":["PMC8909492"],"funding_grant_id":["N/A","P30CA016672"],"pubmed_authors":["Cartwright C","Xie Y","Hitron M","Song IW","Karol M","Vining D","Vo HH","Tsimberidou AM","Nogueras Gonzalez GM","Karp DD"],"additional_accession":[]},"is_claimable":false,"name":"Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center.","description":"<b>Background</b>: BBI608 is an investigational reactive oxygen species generator that affects several molecular pathways. We investigated BBI608 combined with immune checkpoint inhibitors in patients with advanced cancers. <b>Methods</b>: BBI608 (orally twice daily) was combined with ipilimumab (3 mg/kg IV every 3 weeks); pembrolizumab (2 mg/kg IV every 3 weeks); or nivolumab (3 mg/kg IV every 4 weeks). We assessed the safety, antitumor activity and the pharmacokinetic profile of BBI combined with immunotherapy. <b>Results:</b> From 1/2017 to 3/2017, 12 patients were treated (median age, 54 years; range, 31-78; 6 men). Treatment was overall well tolerated. No dose-limiting toxicity was observed. The most common adverse events were diarrhea (5 patients: grade (G)1-2, <i>n</i> = 3; G3, <i>n","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-04-08T17:50:55.015Z","creation":"2025-04-04T19:30:39.192Z"},"accession":"S-EPMC8909492","cross_references":{"pubmed":["35267638"],"doi":["10.3390/cancers14051330"]}}